{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:04:42Z","timestamp":1789747482252,"version":"4.0.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"publisher","award":["157072"],"award-info":[{"award-number":["157072"]}],"id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a chronic, fluctuating inflammatory skin disease in which severity assessment relies on subjective clinical scoring. However, these approaches do not capture subclinical inflammation that may precede disease worsening or follow disease resolution. Furthermore, comprehensive research typically requires invasive methods such as skin biopsy, limiting routine use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study developed and evaluated noninvasive, multimodal biomarker models to objectively assess AD severity and detect subclinical disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional observational study (NCT04295824) involving 80 participants aged 11\u201360\u2005years, including healthy controls and individuals with mild to severe AD. Clinical severity and patient-reported outcomes were assessed, and 32 biomarkers spanning invasive to noninvasive modalities were collected from lesional and nonlesional skin. Biomarkers included those measured by structural [e.g. optical coherence tomography (OCT)], biophysical (e.g. transepidermal water loss), molecular (e.g. Fourier-transform infrared spectroscopy) and metabolite assay (skin cell and blood) methods. Lasso regression was used to build predictive models of AD severity and classify subclinical disease in clinically nonlesional skin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A multivariable model comprised of noninvasive OCT imaging-derived biomarkers predicted local AD severity outcomes with good accuracy (r = 0.82). Global severity and patient-reported outcomes could also be predicted with high accuracy (r = 0.95 and r = 0.76, respectively), as long as information regarding the extent of AD was provided to the model. Multimodal classification models distinguished healthy from clinically nonlesional AD skin with excellent performance (area under the curve = 0.94, 95% confidence interval 0.88\u20130.98), suggesting sensitivity to subclinical inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A comprehensive, patient-centred skin assessment approach can reliably determine AD severity and detect subclinical activity that traditional scoring methods may overlook. Robust OCT-derived metrics highlight the potential of integrating noninvasive, objective tools into clinical workflows to complement standard evaluations and improve treatment strategies. These methods also offer a more objective assessment of disease activity in clinical trials and practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag343","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:46:03Z","timestamp":1787139963000},"source":"Crossref","is-referenced-by-count":0,"title":["Noninvasive biomarker models for objective severity assessment and detection of subclinical inflammation in nonlesional atopic dermatitis"],"prefix":"10.1093","author":[{"given":"Robert A","family":"Byers","sequence":"first","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]},{"name":"INSIGNEO, University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-6413","authenticated-orcid":false,"given":"Paul V","family":"Andrew","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sura","family":"Sahib","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]},{"name":"The Paediatric Dermatology Research Centre, Sheffield Children\u2019s Hospital ,","place":["UK"]},{"name":"Department of Dermatology, The Royal Hallamshire Hospital , Sheffield ,","place":["UK"]},{"name":"Sheffield Children\u2019s NIHR Commercial Research Delivery Centre , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oludolapo","family":"Katibi","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]},{"name":"The Paediatric Dermatology Research Centre, Sheffield Children\u2019s Hospital ,","place":["UK"]},{"name":"Dermatology Unit, Department of Paediatrics, University of Ilorin ,","place":["Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Brown","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Poyner","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chittock","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Williams","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnson","sequence":"additional","affiliation":[{"name":"The Paediatric Dermatology Research Centre, Sheffield Children\u2019s Hospital ,","place":["UK"]},{"name":"Sheffield Children\u2019s NIHR Commercial Research Delivery Centre , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Wright","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, The Royal Hallamshire Hospital , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta C","family":"Martel","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Arlert","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole\u00a0E","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]},{"name":"Division of Dermatology and Venereology, Department of Clinical Sciences, Lund University , Lund ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P","family":"Thyssen","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Matcher","sequence":"additional","affiliation":[{"name":"School of Electronic & Electrical Engineering, The University of Sheffield , Sheffield ,","place":["UK"]},{"name":"INSIGNEO, University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Cork","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]},{"name":"The Paediatric Dermatology Research Centre, Sheffield Children\u2019s Hospital ,","place":["UK"]},{"name":"Department of Dermatology, The Royal Hallamshire Hospital , Sheffield ,","place":["UK"]},{"name":"Sheffield Children\u2019s NIHR Commercial Research Delivery Centre , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon G","family":"Danby","sequence":"additional","affiliation":[{"name":"Sheffield Dermatology Research, School of Medicine & Population Health, The University of Sheffield Medical School , Beech Hill Road, Sheffield ,","place":["UK"]},{"name":"INSIGNEO, University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026091811164985900_ljag343-B1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"2026091811164985900_ljag343-B2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2011.01295.x","article-title":"Health-related quality of life in patients with atopic dermatitis","volume":"39","author":"Maksimovi\u0107","year":"2012","journal-title":"J Dermatol"},{"key":"2026091811164985900_ljag343-B3","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1111\/ijd.14763","article-title":"Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis","volume":"59","author":"Birdi","year":"2020","journal-title":"Int J Dermatol"},{"key":"2026091811164985900_ljag343-B4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2222.2004.1935.x","article-title":"Burden of allergic disease in the UK: secondary analyses of national databases","volume":"34","author":"Gupta","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"2026091811164985900_ljag343-B5","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1111\/jdv.18481","article-title":"Systematic literature review assessing the overall costs and societal impacts of moderate-to-severe atopic dermatitis in Europe","volume":"36","author":"Augustin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026091811164985900_ljag343-B6","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2026091811164985900_ljag343-B7","doi-asserted-by":"crossref","first-page":"100116","DOI":"10.1016\/j.gpeds.2023.100116","article-title":"The therapy of atopic dermatitis in acute phase and in remission","volume":"7","author":"Giannetti","year":"2023","journal-title":"Glob Pediatr"},{"key":"2026091811164985900_ljag343-B8","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaci.2025.03.033","article-title":"Subclinical inflammation precedes atopic dermatitis relapses","volume":"156","author":"Al","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026091811164985900_ljag343-B9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.5021\/ad.2016.28.6.684","article-title":"Four years prospective study of natural history of atopic dermatitis aged 7\u223c8\u2005years at an individual level: a community-based survey by dermatologists\u2019 skin examination in childhood","volume":"28","author":"Kim","year":"2016","journal-title":"Ann Dermatol"},{"key":"2026091811164985900_ljag343-B10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","article-title":"Disease modification in inflammatory skin disorders: opportunities and challenges","volume":"22","author":"Bieber","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2026091811164985900_ljag343-B11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2026091811164985900_ljag343-B12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis","volume":"10","author":"Hanifin","year":"2001","journal-title":"EASI Evaluator Group. Exp Dermatol"},{"key":"2026091811164985900_ljag343-B13","first-page":"23","article-title":"Dermatology","volume":"186","author":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis","year":"1993","journal-title":"Dermatology"},{"key":"2026091811164985900_ljag343-B14","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1111\/all.14492","article-title":"EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers","volume":"75","author":"Bakker","year":"2020","journal-title":"Allergy"},{"key":"2026091811164985900_ljag343-B15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/jid.2010.369","article-title":"Atopic dermatitis diagnostic criteria and outcome measures for clinical trials: still a mess","volume":"131","author":"Flohr","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2026091811164985900_ljag343-B16","first-page":"67","article-title":"Epidermal changes in atopic dermatitis","volume":"114","author":"van Neste","year":"1985","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"key":"2026091811164985900_ljag343-B17","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1364\/BOE.9.002001","article-title":"Sub-clinical assessment of atopic dermatitis severity using angiographic optical coherence tomography","volume":"9","author":"Byers","year":"2018","journal-title":"Biomed Opt Express"},{"key":"2026091811164985900_ljag343-B18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/000155500750042943","article-title":"Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children","volume":"80","author":"Eberlein-K\u00f6nig","year":"2000","journal-title":"Acta Derm Venereol"},{"key":"2026091811164985900_ljag343-B19","first-page":"332","article-title":"The early phase of epidermal barrier regeneration is faster in patients with atopic eczema","volume":"195","author":"Gfesser","year":"1997","journal-title":"Dermatology"},{"key":"2026091811164985900_ljag343-B20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2340\/0001555575429433","article-title":"Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin","volume":"75","author":"Seidenari","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"2026091811164985900_ljag343-B21","doi-asserted-by":"crossref","first-page":"e12043","DOI":"10.1002\/clt2.12043","article-title":"Dynamic trends in skin barrier function from birth to age 6\u2005months and infantile atopic dermatitis: a Chinese prospective cohort study","volume":"11","author":"Ye","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"2026091811164985900_ljag343-B22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaci.2010.12.1124","article-title":"Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities","volume":"127","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2026091811164985900_ljag343-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2009.04.006","article-title":"A possible mechanism underlying the ceramide deficiency in atopic dermatitis: expression of a deacylase enzyme that cleaves the N-acyl linkage of sphingomyelin and glucosylceramide","volume":"55","author":"Imokawa","year":"2009","journal-title":"J Dermatol Sci"},{"key":"2026091811164985900_ljag343-B24","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2013.1973","article-title":"Skin barrier dysfunction in non-lesional atopic eczema: the role of stratum corneum lipids","author":"van Smeden","year":"2013","journal-title":"Eur J Dermatol"},{"key":"2026091811164985900_ljag343-B25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5021\/ad.2012.24.3.253","article-title":"Long term treatment concepts and proactive therapy for atopic eczema","volume":"24","author":"Wollenberg","year":"2012","journal-title":"Ann Dermatol"},{"key":"2026091811164985900_ljag343-B26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/09546634.2016.1201189","article-title":"Assessment of \u201ccorticophobia\u201d as an indicator of non-adherence to topical corticosteroids: a pilot study","volume":"28","author":"Mueller","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"2026091811164985900_ljag343-B27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1398-9995.2008.01803.x","article-title":"Proactive therapy of atopic dermatitis \u2013 an emerging concept","volume":"64","author":"Wollenberg","year":"2009","journal-title":"Allergy"},{"key":"2026091811164985900_ljag343-B28","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jaci.2013.12.1079","article-title":"Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful?","volume":"133","author":"Tang","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2026091811164985900_ljag343-B29","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis \u2013 a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026091811164985900_ljag343-B30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ced\/llad416","article-title":"Characterization of skin barrier defects using infrared spectroscopy in patients with atopic dermatitis","volume":"49","author":"Williams","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026091811164985900_ljag343-B31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0140-6736(05)65466-9","article-title":"Diagnostic criteria for atopic dermatitis","volume":"348","author":"Williams","year":"1996","journal-title":"Lancet"},{"key":"2026091811164985900_ljag343-B32","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective","volume":"140","author":"Charman","year":"2004","journal-title":"Arch Dermatol"},{"key":"2026091811164985900_ljag343-B33","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1007\/s11357-024-01199-9","article-title":"Quantification of age-related changes in the structure and mechanical function of skin with multiscale imaging","volume":"46","author":"Woessner","year":"2024","journal-title":"GeroScience"},{"key":"2026091811164985900_ljag343-B34","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/jid.2008.280","article-title":"Clinical severity correlates with impaired barrier in filaggrin-related eczema","volume":"129","author":"Nemoto-Hasebe","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2026091811164985900_ljag343-B35","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1365-2133.2010.10068.x","article-title":"Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3\u2005months of age","volume":"163","author":"Flohr","year":"2010","journal-title":"Br J Dermatol"},{"key":"2026091811164985900_ljag343-B36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/tjem.tjem_182_23","article-title":"Receiver operating characteristic curve analysis in diagnostic accuracy studies: a guide to interpreting the area under the curve value","volume":"23","author":"\u00c7orbac\u0131o\u011flu","year":"2023","journal-title":"Turk J Emerg Med"},{"key":"2026091811164985900_ljag343-B37","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1364\/AO.46.001782","article-title":"Correlation between optical coherence tomography images and histology of pigskin","volume":"46","author":"Kuranov","year":"2007","journal-title":"Applied Optics"},{"key":"2026091811164985900_ljag343-B38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1468-3083.2006.01629.x","article-title":"Epidermal thickness assessed by optical coherence tomography and routine histology: preliminary results of method comparison","volume":"20","author":"Gambichler","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026091811164985900_ljag343-B39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2026091811164985900_ljag343-B40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/jcm4050858","article-title":"Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics","volume":"4","author":"Mansouri","year":"2015","journal-title":"J Clin Med"},{"key":"2026091811164985900_ljag343-B41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/pai.12607","article-title":"Elevated blood eosinophils in early infancy are predictive of atopic dermatitis in children with risk for atopy","volume":"27","author":"Rossberg","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"2026091811164985900_ljag343-B42","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1046\/j.1365-2133.2001.04456.x","article-title":"Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining","volume":"145","author":"Kiehl","year":"2001","journal-title":"Br J Dermatol"},{"key":"2026091811164985900_ljag343-B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.02.007","article-title":"Transepidermal water loss and skin site: a hypothesis","volume":"373","author":"Hadgraft","year":"2009","journal-title":"Int J Pharm"},{"key":"2026091811164985900_ljag343-B44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.yexcr.2016.05.004","article-title":"Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin","volume":"345","author":"Donetti","year":"2016","journal-title":"Exp Cell Res"},{"key":"2026091811164985900_ljag343-B45","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1398-9995.2010.02540.x","article-title":"Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity","volume":"66","author":"Kezic","year":"2011","journal-title":"Allergy"},{"key":"2026091811164985900_ljag343-B46","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.3390\/ijms26178394","article-title":"Fibrotic disease of the skin and lung: shared pathways, environmental drivers, and therapeutic opportunities in a changing climate","volume":"26","author":"Grafanaki","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026091811164985900_ljag343-B47","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.4049\/jimmunol.1100504","article-title":"IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin","volume":"186","author":"Oh","year":"2011","journal-title":"J Immunol"},{"key":"2026091811164985900_ljag343-B48","doi-asserted-by":"crossref","first-page":"040503","DOI":"10.1117\/1.3567082","article-title":"Dermal reflectivity determined by optical coherence tomography is an indicator of epidermal hyperplasia and dermal edema within inflamed skin","volume":"16","author":"Phillips","year":"2011","journal-title":"J Biomed Opt"},{"key":"2026091811164985900_ljag343-B49","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1111\/all.14842","article-title":"Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis","volume":"76","author":"Rinaldi","year":"2021","journal-title":"Allergy"},{"key":"2026091811164985900_ljag343-B50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/all.15895","article-title":"Electrical impedance spectroscopy detects skin barrier dysfunction in childhood atopic dermatitis","volume":"79","author":"Sasaki","year":"2024","journal-title":"Allergy"},{"key":"2026091811164985900_ljag343-B51","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms23052684","article-title":"Multiple roles for cytokines in atopic dermatitis: from pathogenic mediators to endotype-specific biomarkers to therapeutic targets","volume":"23","author":"Fania","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026091811164985900_ljag343-B52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2024.09.022","article-title":"The paradigm shift in drug development for atopic dermatitis: addressing the variables of the equation leading to disease modification","volume":"134","author":"Bieber","year":"2025","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag343\/70717999\/ljag343.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag343\/70717999\/ljag343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:17:03Z","timestamp":1789744623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljag343\/8766872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":52,"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag343","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"ljag343"}}